<DOC>
	<DOCNO>NCT02041845</DOCNO>
	<brief_summary>The majority patient limited disease small cell lung cancer ( SCLC ) experience recurrent disease despite receive concurrent chemoradiotherapy . New agent dose-escalation chemotherapy provide survival benefit . Local failure account high proportion recurrence . Improved thoracic radiotherapy ( TRT ) might increase local control thus reduce recurrence rate prolong survival . Positron emission tomography ( PET CT ) well stag SCLC computer tomography ( CT ) bone scan . More precise localization tumor lead accurate definition target volume TRT reduce radiation dose normal tissue . A large proportion patient relapse die within one two year therapy . Few patient survive long three year . Thus , two-year survival consider clinically highly relevant measure efficacy . The aim study compare two schedule TRT respect local control , progression free survival , overall survival , toxicity health-related quality life . In addition patient best outcomes tolerate chemoradiotherapy characterize ( e.g . clinical characteristic , blood biomarkers , body composition ) .</brief_summary>
	<brief_title>Two Schedules Hyperfractionated Thoracic Radiotherapy Limited Disease Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm smallcell lung cancer ( SCLC ) Limited disease ( stage IIIII ) Stage I ineligible surgery Eastern Cooperative Oncology Group ( ECOG ) Performance 02 Measureable disease accord Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 Adequate organ function define : ( ) Serum serum alanine transaminase ( ALT ) ≤ 3 x upper limit normal ( ULN ) ; ( b ) Total serum bilirubin ≤ 1.5 x ULN ; ( c ) Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L ; ( ) Platelets ≥ 100 x 109/L ; ( e ) Creatinine &lt; 100 µmol/L calculate creatinineclearance &gt; 50 ml/min . If calculate creatinineclearance &lt; 50 ml/min , ethylene diamine tetraacetic acid ( EDTA ) clearance perform . Pulmonary function : Forced Expiratory Volume One Second ( FEV1 ) &gt; 1 l 30 % predict value diffuse capacity lung carbon monoxide ( DLCO ) &gt; 30 % predict value All fertile patient use safe contraception Written inform consent prior systemic therapy smallcell lung cancer Previous radiotherapy thorax malignant cell pericardial pleural fluid ( least one sample analyse pleural fluid present serious concomitant systemic disorder ( example active infection , unstable cardiovascular disease ) opinion investigator would compromise patient 's ability complete study interfere evaluation efficacy safety study treatment condition medical , social , psychological could prevent adequate information followup clinically active cancer SCLC . Hormonal therapy prostate cancer breast cancer basocellular carcinoma skin allow pregnancy , lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>Radiotherapy dosage</keyword>
	<keyword>Dose fractionation</keyword>
	<keyword>Radiotherapy , image-guided</keyword>
	<keyword>Thorax</keyword>
</DOC>